Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: SABMiller Rises But FTSE 100 Hit By China Data

Tue, 13th Oct 2015 07:39

LONDON (Alliance News) - UK shares opened lower, weighed down by weak economic data from China, while SABMiller led the gainers in London after it agreed to GBP71.28 billion takeover by brewing rival Anheuser-Busch InBev.

AB InBev lifted its offer to GBP44.00 per share, and its smaller rival said it will be willing to recommend a bid at that price to its shareholders. The previous offer valued SABMiller at GBP43.50 per share.

In the event of an offer, AB InBev said it would agree to a "best efforts" commitment to secure regulatory approvals required for the deal to go through. A USD3 billion break fee would be paid to SABMiller in the event that an agreed deal fell through due to a failure to obtain regulatory clearances or the approval of AB InBev shareholders.

In addition, SABMiller shareholders will be entitled to any dividends declared or paid in the period to September 30 or March 31 ahead of completion of a possible deal. Dividends could amount to a maximum of USD1.22 per share over the two periods.

No formal offer has been made. AB InBev now has until 1700 BST on October 28 to decide whether to make an firm offer or walk away.

The FTSE 100 index was down 0.5% at 6,337.35, the FTSE 250 was down 0.5% at 16,902.43, and the AIM All-Share was down 0.1% at 734.29. In Europe, the French CAC 40 index and the German DAX 30 were down 1.1% and 0.6%, respectively.

Asian stocks also were mixed on Tuesday. The Japanese Nikkei 225 index ended down 1.1%, reopening after a holiday on Monday. In China, the Hang Seng index in Hong Kong was off 0.6%, but the Shanghai Composite closed up 0.2%, following weak economic data from the Asian giant.

China's exports declined at a moderate pace in September as the devaluation of yuan helped it from falling sharply amid weak global demand. At the same time, imports plunged due to a drop in commodity prices and subdued domestic demand.

On a yearly basis, exports slid 1.1% in September, compared to a 5.5% decline seen in August, the General Administration of Customs reported Tuesday. Economists had forecast it to drop at a faster pace of 6.3%.

Meanwhile, imports logged a sharp 17.7% contraction after falling 13.8% a month ago. This was the eleventh straight annual decline in imports. Imports were expected to decline 15%.

The trade surplus totalled USD60.34 billion, bigger than a USD48.2 billion surplus expected by economists.

"The deterioration in recent Chinese trade data has reinforced concerns about the health of the Chinese economy as sliding commodity prices and weak consumer demand has seen both imports and exports slow much more than expected in the months since June," said CMC Markets chief market analyst Michael Hewson.

"The numbers also suggest that next week?s gross domestic product could well come in well below the 7% threshold targeted by Chinese officials as their GDP target," Hewson added.

Outside China, the German consumer price index came in line with economists expectations. Month-on-month, Germany's CPI fell 0.2%, matching an similar 0.2% decline seen in August. Meanwhile, on a yearly basis, inflation came in flat at 0%.

Still in the economic calendar, the ZEW surveys for Germany and the EU are due at 1000 BST. Meanwhile, the consumer, retail and producer price indices from the UK are expected at 0930 BST, while at the same time the Bank of England releases its credit conditions survey. In the US, the Redbook index is due at 1355 BST.

"Last month saw the [UK] headline CPI rate, which has fluctuated between 0.1% and -0.1% year-on-year since February, fall back by 0.1 percentage point to 0.0%, partly on the back of weaker petrol prices and a 0.2 percentage points drop in core inflation to 1.0%," said Jonathan Thomas, senior economist at Lloyds Bank.

"The initial impacts from a fall in trade-weighted sterling and pickup in oil prices since mid-August are set to be countered by a further dip in forecourt prices and cuts to domestic gas tariffs in September. Thus we expect both the headline and core rates to remain unchanged," Thomas added.

On the London Stock Exchange, Royal Mail was the top faller in the FTSE 100, down 4.5%, after the UK government said it has sold the majority of its 14% stake in the group for around GBP591.0 million under an accelerated bookbuilding process that was announced late Monday.

The government said it has sold a 13% stake in the company, comprised of around 130.0 million shares, at a placing price of 455.0 pence per share, generating proceeds of GBP591.1 million.

The government owned a 14% stake in Royal Mail, leaving it with a 1% shareholding after the placing. That remaining 1% stake, comprised of around 10.0 million shares, will be "gifted" to Royal Mail employees in the UK, marking the government's final disposal of shares.

Concerns about China's economy health were hitting London-listed mining stocks. Glencore was down 3.5%, Anglo American down 2.9% and BHP Billiton down 2.0%. Among mid-caps, KAZ Minerals was down 5.8% and Vedanta Resources was off 1.7%.

Going in the opposite direction was GlaxoSmithKline, up 1.0%, after JPMorgan upgraded the drugmaker to Neutral from Underweight.

In the FTSE 250, Bellway was the top performer, up 3.9%. The housebuilder said it should be able to grow volumes by up to 10% in its current financial year, as the group reported a 44% jump in pretax profit in its most recent financial year and raised its dividend.

In a statement, Bellway said pretax profit amounted to GBP354.2 million in the year ended July 31, compared with GBP246.0 million in the prior year, as revenue swelled to GBP1.77 billion from GBP1.48 billion. The housebuilder lifted its full-year dividend per share by 48% to 77.0 pence from 52.0p.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.